ImmuPharma Financial Statements From 2010 to 2025

Stocks . UK . 
Stock . ImmuPharma PLC
IMM Stock   3.40  0.16  4.49%   
ImmuPharma PLC financial statements provide useful quarterly and yearly information to potential ImmuPharma PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ImmuPharma PLC financial statements helps investors assess ImmuPharma PLC's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ImmuPharma PLC's valuation are summarized below:
Gross Profit
-70 K
Exchange Market
LSE - AIM
Market Capitalization
14.8 M
Enterprise Value Revenue
73.6224
Revenue
-70 K
There are over eighty-two available fundamental trends for ImmuPharma PLC, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of ImmuPharma PLC's regular performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

ImmuPharma PLC Total Revenue

118,350

Check ImmuPharma PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuPharma PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.5 K, Interest Expense of 2.2 K or Selling General Administrative of 1.7 M, as well as many indicators such as . ImmuPharma financial statements analysis is a perfect complement when working with ImmuPharma PLC Valuation or Volatility modules.
  
This module can also supplement various ImmuPharma PLC Technical models . Check out the analysis of ImmuPharma PLC Correlation against competitors.

ImmuPharma PLC Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.3 M2.4 M6.1 M
Slightly volatile
Other Current Liabilities726.2 K691.7 K254.9 K
Slightly volatile
Total Current Liabilities1.4 M1.9 M1.1 M
Slightly volatile
Total Stockholder Equity903.1 K950.7 K4.8 M
Slightly volatile
Cash178.3 K187.6 K3.3 M
Slightly volatile
Non Current Assets Total1.4 M1.6 M1.5 M
Slightly volatile
Cash And Short Term Investments178.3 K187.6 K3.3 M
Slightly volatile
Common Stock Total Equity30.2 M28.8 M16.1 M
Slightly volatile
Common Stock Shares Outstanding437.1 M416.3 M183.2 M
Slightly volatile
Liabilities And Stockholders Equity2.3 M2.4 M6.1 M
Slightly volatile
Other Current Assets1.3 M1.3 M1.4 M
Pretty Stable
Other Stockholder Equity35.4 M33.7 M19.7 M
Slightly volatile
Total Liabilities1.7 M1.9 M1.4 M
Pretty Stable
Total Current Assets1.1 M1.2 M4.8 M
Slightly volatile
Common Stock36 M34.3 M17.6 M
Slightly volatile
Short and Long Term Debt Total94.9199.9393.9 K
Slightly volatile
Property Plant And Equipment Net181.9 K117.4 K207.2 K
Slightly volatile
Accounts Payable760.8 K892.6 K622.9 K
Slightly volatile
Net Receivables950.7 K788.5 K944.1 K
Pretty Stable
Property Plant And Equipment Gross280.6 K221.2 K326.6 K
Slightly volatile
Short Term Debt94.9199.9165.7 K
Slightly volatile
Intangible Assets477.8 K402.8 K528.9 K
Slightly volatile
Property Plant Equipment426.2 K405.9 K253.9 K
Slightly volatile
Net Tangible Assets5.2 M2.8 M4.5 M
Very volatile
Other Liabilities116.1 K225.4 K113.7 K
Slightly volatile
Capital Surpluse25.6 M31.3 M21.8 M
Slightly volatile
Net Invested Capital903.1 K950.7 K4 M
Pretty Stable
Long Term Investments1.6 M1.8 M2 M
Slightly volatile
Capital Stock26.2 M34.3 M19.7 M
Slightly volatile
Good Will0.80.90.9813
Slightly volatile
Deferred Long Term Liabilities323.3 K363.7 K396.5 K
Slightly volatile

ImmuPharma PLC Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization84.5 K43.2 K90.2 K
Pretty Stable
Interest Expense2.2 K2.3 K403.4 K
Slightly volatile
Selling General Administrative1.7 M1.2 M1.5 M
Pretty Stable
Other Operating Expenses5.1 M3.5 M4.7 M
Pretty Stable
Total Operating Expenses5.1 M3.5 M4.7 M
Pretty Stable
Research Development3 M2.3 M2.7 M
Pretty Stable
Interest Income3.3 K3.5 K6.9 K
Slightly volatile
Reconciled Depreciation32.2 K33.8 K114.6 K
Slightly volatile
Selling And Marketing Expenses112.2 K126.2 K137.6 K
Slightly volatile

ImmuPharma PLC Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow571 K601 K4.3 M
Slightly volatile
Other Non Cash Items1.1 M1 M602 K
Slightly volatile
End Period Cash Flow178.3 K187.6 K3.3 M
Slightly volatile
Depreciation41.1 K43.2 K87.2 K
Pretty Stable
Sale Purchase Of Stock6.5 M9.2 M5.5 M
Slightly volatile
Issuance Of Capital Stock1.3 M1.3 M6.9 M
Slightly volatile

ImmuPharma Fundamental Market Drivers

Cash And Short Term Investments208.5 K

About ImmuPharma PLC Financial Statements

ImmuPharma PLC stakeholders use historical fundamental indicators, such as ImmuPharma PLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although ImmuPharma PLC investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImmuPharma PLC's assets and liabilities are reflected in the revenues and expenses on ImmuPharma PLC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImmuPharma PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-437.1 K-458.9 K
Cost Of Revenue33.8 K32.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Other Information on Investing in ImmuPharma Stock

ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY